| P50 | author | Giuseppe Palmieri | Q30505581 |
| | Ena Wang | Q114521261 |
| | Maria Libera Ascierto | Q114522891 |
| | Sara Civini | Q114523156 |
| | Jennifer Reinboth | Q114523158 |
| | Muna Al Hashmi | Q114523159 |
| | Qiuzhen Liu | Q114523160 |
| | Ben D Ayotte | Q114523162 |
| | Andrea Worschech | Q114523163 |
| | Lorenzo Uccellini | Q114523164 |
| | Davide Bedognetti | Q39187019 |
| | Michele Sommariva | Q58386880 |
| | David F Stroncek | Q88057669 |
| | Paolo Antonio Ascierto | Q89457677 |
| | Lotfi Chouchane | Q98163574 |
| | Francesco Marincola | Q107723823 |
| P2093 | author name string | Valeria De Giorgi | |
| | Sara Tomei | |
| P2860 | cites work | Main roads to melanoma | Q21245465 |
| | Melanoma: new insights and new therapies | Q26853127 |
| | The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures | Q27015137 |
| | NRAS mutation status is an independent prognostic factor in metastatic melanoma | Q27851695 |
| | Mutations of the BRAF gene in human cancer | Q27860760 |
| | Raf kinases in cancer-roles and therapeutic opportunities | Q28237793 |
| | Distinct sets of genetic alterations in melanoma | Q29614965 |
| | Molecular classification of cutaneous malignant melanoma by gene expression profiling | Q29619204 |
| | Improving melanoma classification by integrating genetic and morphologic features | Q33340639 |
| | Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme | Q33750137 |
| | High frequency of BRAF mutations in nevi | Q34160519 |
| | The stable traits of melanoma genetics: an alternate approach to target discovery | Q34248355 |
| | The role of BRAF V600 mutation in melanoma | Q34637951 |
| | A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? | Q35069175 |
| | SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery | Q35298744 |
| | Novel Protein Targeted Therapy of Metastatic Melanoma | Q35557067 |
| | Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma | Q35621653 |
| | Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma | Q35782064 |
| | A genetic inference on cancer immune responsiveness | Q36057497 |
| | The role of B-RAF in melanoma. | Q36078119 |
| | Melanoma biology and new targeted therapy | Q36742015 |
| | IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes | Q37003368 |
| | CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. | Q37279217 |
| | Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside | Q37301003 |
| | Molecular pathogenesis of cutaneous melanocytic neoplasms | Q37463075 |
| | BRAF signaling and targeted therapies in melanoma | Q37493375 |
| | NRAS mutant melanoma: biological behavior and future strategies for therapeutic management | Q37689575 |
| | Review and cross-validation of gene expression signatures and melanoma prognosis. | Q37940188 |
| | Small molecule inhibitors of BRAF in clinical trials | Q37973551 |
| | Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. | Q38195656 |
| | Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines | Q38329529 |
| | BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. | Q39212469 |
| | Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma | Q39304634 |
| | Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma | Q39812581 |
| | Confirmation of a BRAF mutation-associated gene expression signature in melanoma. | Q40129786 |
| | The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells | Q40262620 |
| | Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma | Q40319765 |
| | B-RAF is a therapeutic target in melanoma | Q40543086 |
| | Microarray expression profiling in melanoma reveals a BRAF mutation signature. | Q40572664 |
| | Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas | Q41251515 |
| | Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene. | Q41444187 |
| | Common pathways to tumor rejection | Q42263938 |
| | A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion | Q42674919 |
| | High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma | Q44387406 |
| | Prediction of response to anticancer immunotherapy using gene signatures | Q44721413 |
| | Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma | Q47573472 |
| | BRAF mutations are common somatic events in melanocytic nevi | Q47978923 |
| | BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma | Q48499411 |
| | Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome | Q48661799 |
| | Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. | Q50954469 |
| | Mitogen-actived protein kinase activation is an early event in melanoma progression. | Q53745580 |
| | NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. | Q54570448 |
| | Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. | Q54587263 |
| | Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation | Q73013877 |
| | BRAF and RAS mutations in human lung cancer and melanoma | Q78598197 |
| P433 | issue | 1 | |
| P304 | page(s) | 93-104 | |
| P577 | publication date | 2014-08-06 | |
| P1433 | published in | Molecular Oncology | Q2190736 |
| P1476 | title | The immune-related role of BRAF in melanoma. | |
| P478 | volume | 9 | |